Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02150551 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease
A Phase 1 study, sponsored by Catherine Bollard.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02150551 is a Phase 1 study that has completed, run by Catherine Bollard. The registered enrollment target is 1 participants.
The verdict
NCT02150551, a Phase 1 study, has completed, sponsored by Catherine Bollard.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
In this trial, investigators will infuse donor bone marrow mesenchymal stromal cells intravenously, as a treatment for pediatric Crohn's disease or ulcerative colitis that has not responded to conventional therapies. The goals of this study are to test the safety and tolerability of donor mesenchymal stromal cells in children with Inflammatory Bowel Disease. Mesenchymal stromal cells support the development of blood cells within the bone marrow. When isolated from a donor and infused into an animal or human, they have been demonstrated to travel to areas of inflammation, to alter immune responses, to decrease pro-inflammatory cytokines, and to promote tissue repair. Infusion of these cells does not lead to rejection. These properties lead investigators to hypothesize that that these may be they may be beneficial in treating inflammatory bowel disease.
Interventions
- BIOLOGICAL Allogeneic bone marrow-derived mesenchymal stromal cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-06-07 |
| Est. Completion | 2018-09-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02150551
The ClinicalTrials.gov registry entry for NCT02150551 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catherine Bollard, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allogeneic bone marrow-derived mesenchymal stromal cells is the first listed.
NCT02150551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02150551 about?
NCT02150551 is a clinical study titled "Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease". In this trial, investigators will infuse donor bone marrow mesenchymal stromal cells intravenously, as a treatment for pediatric Crohn's disease or ulcerative colitis that has not responded to conventional therapies. The goals of this study are to test the safety and tolerability of donor mesenchyma...
What is the current status of trial NCT02150551?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2018-06-07. Estimated completion is 2018-09-05.
What interventions are being tested in trial NCT02150551?
The interventions under investigation include: Allogeneic bone marrow-derived mesenchymal stromal cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02150551?
This trial is sponsored by Catherine Bollard, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.